(63 days)
No
The document describes contact lenses and their intended use, with no mention of AI or ML technology in the device description, intended use, or performance studies.
No
The device is indicated for correcting refractive errors (myopia, hyperopia, astigmatism, presbyopia) for vision correction, and for protection against UV radiation, none of which are considered therapeutic treatments for disease.
No
Explanation: The ACUVUE Contact Lens is described as a device for the correction of refractive ametropia and presbyopia, indicating it is a corrective, not a diagnostic, device. Its intended use is to improve vision, not to detect or monitor disease.
No
The device description and intended use clearly describe contact lenses, which are physical medical devices, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the ACUVUE Contact Lenses are for the correction of refractive ametropia (myopia, hyperopia, astigmatism) and presbyopia. This is a therapeutic or corrective function, not a diagnostic one.
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body (like blood, urine, or tissue) to detect diseases, conditions, or infections. Contact lenses do not perform this type of analysis.
- Device Description and Performance Studies: The description and performance studies focus on the physical properties and clinical safety of the contact lenses for vision correction, not on any diagnostic capabilities.
Therefore, the ACUVUE Contact Lens, as described, is a medical device for vision correction, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The ACUVUE Contact Lens (spherical) is indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia) in aphakic or non-aphakic persons with non-diseased eves who may have 1.00 D or less of astigmatism.
The ACUVUE BIFOCAL Contact Lens is indicated for daily wear for the correction of distance and near vision in presbyopic, aphakic or non-aphakic persons with non-diseased eyes who may have 0.75 D or less of astigmatism.
The ACUVUE TORIC Contact Lens is indicated for daily wear for the correction of visual acuity in aphakic or non-aphakic persons with non-diseased eyes that are hyperopic or myopic and may have 10.00 D or less of astigmatism.
The ACUVUE TORIC BIFOCAL Contact Lens is indicated for daily wear for the correction of distance and near vision in presbyopic aphakic or non-phakic persons with non-diseased eyes who may have 10.00 D of astigmatism or less.
ACUVUE Contact Lenses help protect against transmission of harmful UV radiation to the cornea and into the eye.
Eye care practitioners may prescribe the lens for either single-use disposable wear or for frequent/planned replacement wear, with cleaning, disinfection and scheduled replacement. When prescribed for frequent/planned replacement wear, the lens may be disinfected using a chemical disinfection system only.
Product codes
86 LPL
Device Description
The device description does not change from that cleared under K991134.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
eyes, cornea
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Eye care practitioners
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
This 510(k) describes a labeling modification which is supported by clinical studies published in the July 1999 CLAO Journal (see Attachment A). There is no change in lens material, the manufacturing process, nor the parameters and properties, therefore, the clinical data previously submitted in K991134 supports the clinical safety of the subject device.
Additional studies were not conducted, therefore, the conclusions drawn from studies previously submitted in K991134 support the non-clinical and clinical safety of the subject device. The clinical studies published in the July 1999 CLAO Journal support the labeling modification that is the subject of this 510(k).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 886.5925 Soft (hydrophilic) contact lens.
(a)
Identification. A soft (hydrophilic) contact lens is a device intended to be worn directly against the cornea and adjacent limbal and scleral areas of the eye to correct vision conditions or act as a therapeutic bandage. The device is made of various polymer materials the main polymer molecules of which absorb or attract a certain volume (percentage) of water.(b)
Classification. (1) Class II if the device is intended for daily wear only.(2) Class III if the device is intended for extended wear.
(c)
Date PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the act is required before a device described in paragraph (b)(2) of this section may be commercially distributed. See § 886.3.
0
FEB 2 3 2000
Summary of 510(k) Submission
K 994324
| Name and
address of
submitter | Vistakon, Johnson & Johnson Vision Products, Inc.
7500 Centurion Parkway
Jacksonville, Florida 32256
Contact: Sharon Briggs
Phone: (904) 443-1471
Date Prepared: December 21, 1999 | | | | |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|
| Identification of
device | The trade name is ACUVUE (etafilcon A) soft (hydrophilic) contact lenses, clear and visibility tinted, with UV blocker, for daily wear The common or usual name is Soft (hydrophilic) Contact Lens (daily wear). The FDA Classification is Class II. | | | | |
| Predicate
devices | The predicate device is ACUVUE (etafilcon A) soft (hydrophilic) contact lenses, clear and visibility tinted, with UV blocker, for daily wear covered under K991134. | | | | |
| Description of
device | The device description does not change from that cleared under K991134. | | | | |
| | Continued on next page | | | | |
1
Summary of 510(k) Submission, Continued
| Indications for
| Use | |
|---|---|
| The ACUVUE Contact Lens (spherical) is indicated for daily wear for | |
| the correction of refractive ametropia (myopia and hyperopia) in | |
| aphakic or non-aphakic persons with non-diseased eyes who may have | |
| 1.00 D or less of astigmatism. | |
| The ACUVUE BIFOCAL Contact Lens is indicated for daily wear for | |
| the correction of distance and near vision in presbyopic, aphakic or | |
| non-aphakic persons with non-diseased eyes who may have 0.75 D or | |
| less of astigmatism. | |
| The ACUVUE TORIC Contact Lens is indicated for daily wear for | |
| the correction of visual acuity in aphakic or non-aphakic persons with | |
| non-diseased eyes that are hyperopic or myopic and may have 10.00 D | |
| or less of astigmatism. | |
| The ACUVUE TORIC BIFOCAL Contact Lens is indicated for daily | |
| wear for the correction of distance and near vision in presbyopic | |
| aphakic or non-phakic persons with non-diseased eyes who may have | |
| 10.00 D of astigmatism or less. | |
| ACUVUE Contact Lenses help protect against transmission of | |
| harmful UV radiation to the cornea and into the eye. | |
| Eye care practitioners may prescribe the lens for either single-use | |
| disposable wear or for frequent/planned replacement wear, with | |
| cleaning, disinfection and scheduled replacement. When prescribed | |
| for frequent/planned replacement wear, the lens may be disinfected | |
| using a chemical disinfection system only. |
2
Summary of 510(k) Submission, Continued
| Reason for
510(k) | The reason for the 510(k) is to revise the "Wear Schedule" in the Draft
Package Insert, and the "Introduction" statements in the Draft Patient
Instruction Guides (Disposable and Frequent Replacement) for ACUVUE
(etafilcon A) soft (hydrophilic) contact lenses, clear and visibility tinted, with
UV blocker, for daily wear to include the following statement:
When ACUVUE UV Blocking Contact Lenses are replaced at intervals
ranging from 1 day to 2 weeks, the risk of developing giant papillary
conjunctivitis may be reduced . |
|--------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Characteristics | The characteristics do not change. They are the same as previously submitted
in K991134. |
| Non-clinical
studies | Non-clinical studies (chemistry, toxicology, microbiology, shelf-life, and
leachability) on the lens material were not conducted because the lens
material, etafilcon A, does not change. |
| Clinical studies | This 510(k) describes a labeling modification which is supported by clinical
studies published in the July 1999 CLAO Journal (see Attachment A). There
is no change in lens material, the manufacturing process, nor the parameters
and properties, therefore, the clinical data previously submitted in K991134
supports the clinical safety of the subject device. |
| Conclusions
drawn from
studies | Additional studies were not conducted, therefore, the conclusions drawn from
studies previously submitted in K991134 support the non-clinical and clinical
safety of the subject device. The clinical studies published in the July 1999
CLAO Journal support the labeling modification that is the subject of this
510(k). |
For the disposable patient guide, the statement is revised to: "When ACUVUE UV Blocking Contact Lenses are replaced daily, the risk of developing giant papillary conjunctivitis may be reduced."
3
Image /page/3/Picture/1 description: The image is a black and white seal for the Department of Health & Human Services - USA. The seal is circular with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. In the center of the seal is a stylized image of three human profiles.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
FEB 2 3 2000
Ms. Sharon A. Briggs Manager, Regulatory Submissions VISTAKON™ 7500 Centurion Parkway Jacksonville, FL 32256
Re: K994324 Trade Name: ACUVUE (etafilcon A) Soft (hydrophilic) Contact Lens Clear and Visibility Tinted with UV blocker Regulatory Class: II -ﺴﻬ Product Code: 86 LPL Dated: December 21, 1999 Received: December 22, 1999
Dear Ms. Briggs:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations .
4
Page 2 - Ms. Sharon A. Briggs
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
ﺔ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤ
A. Ralph Rosenthal
A. Ralph Rosenthal, M.D. Director Division of Ophthalmic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications Statement
510(k) Number (if known): j( 99 4 32 4
ACUVUE (etafilcon A) Soft (hydrophilic) Contact Lens Clear and Visibility Device Name: Tinted with UV blocker
Indication for Use:
The ACUVUE Contact Lens (spherical) is indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia) in aphakic or non-aphakic persons with non-diseased eves who may have 1.00 D or less of astigmatism.
The ACUVUE BIFOCAL Contact Lens is indicated for daily wear for the correction of distance and near vision in presbyopic, aphakic or non-aphakic persons with non-diseased eyes who may have 0.75 D or less of astigmatism.
The ACUVUE TORIC Contact Lens is indicated for daily wear for the correction of visual acuity in aphakic or non-aphakic persons with non-diseased eyes that are hyperopic or myopic and may have 10.00 D or less of astigmatism.
The ACUVUE TORIC BIFOCAL Contact Lens is indicated for daily wear for the correction of distance and near vision in presbyopic aphakic or non-phakic persons with non-diseased eyes who may have 10.00 D of astigmatism or less.
ACUVUE Contact Lenses help protect against transmission of harmful UV radiation to the cornea and into the eye.
Eye care practitioners may prescribe the lens for either single-use disposable wear or for frequent/planned replacement wear, with cleaning, disinfection and scheduled replacement. When prescribed for frequent/planned replacement wear, the lens may be disinfected using a chemical disinfection system only.
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use | OR | Over the Counter | ||
|---|---|---|---|---|
| antist | ||||
| (Division Sign-Off) | ||||
| Division of Ophthalmic Devices | ||||
| 510(k) Number上9 94324 |